Filing Flows › Ligand Pharmaceuticals (LGND) › Free cash flow
Ligand Pharmaceuticals (LGND) free cash flow by quarter
Ligand Pharmaceuticals' free cash flow was $24.0M in Q2 2026 (second quarter 2026), -50% from Q1 2026. Over the last 5 quarters it ranged from $13.1M (Q3 2025) to $48.5M (Q1 2026).
| Quarter | Free cash flow | Q/Q | Y/Y |
|---|---|---|---|
| Q2 2026 | $24.0M | -50% | +54% |
| Q1 2026 | $48.5M | +6% | — |
| Q4 2025 | $45.9M | +251% | — |
| Q3 2025 | $13.1M | -16% | — |
| Q2 2025 | $15.6M | — | — |
Q2 2026 at a glance
Ligand Pharmaceuticals, Q2 2026: revenue $63.7M (+34% year over year), operating margin 13.5%, net earnings $48.5M, operating cash flow $24.0M. The chart follows the revenue to costs, profit and cash.
Questions
What is Ligand Pharmaceuticals' free cash flow?
Ligand Pharmaceuticals' free cash flow was $24.0M in Q2 2026 (second quarter 2026), -50% from Q1 2026.
How has Ligand Pharmaceuticals' free cash flow changed?
Over the last 5 quarters it ranged from $13.1M (Q3 2025) to $48.5M (Q1 2026).
Q2 2026 results → · How Ligand Pharmaceuticals makes money →